(±)-trans-2-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-(N-methyl-N- hydroxyureidyl)methylphenyl]-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran (CMI- 392), a potent dual 5-lipoxygenase inhibitor and platelet-activating factor receptor antagonist

Journal of Medicinal Chemistry

Volumn 41, Issue 11, 1998, Pages 1970-1979

  Cai, Xiong ^a   Scannell, Ralph T ^a   Yaeger, David ^a   Hussoin, Md Sajjat ^a   Killian, David B ^a   Qian, Changgeng ^a   Eckman, Joseph ^a   Hwang, San Bao ^a   Libertine Garahan, Lynn ^a   Yeh, C Grace ^a   Ip, Stephen H ^a   Shen, T Y ^b  

^a CytoMed Inc   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [3 METHOXY 4 (4 CHLOROPHENYLTHIOETHOXY) 5 (N METHYL N HYDROXYUREIDYL)METHYLPHENYL] 5 (3,4,5 TRIMETHOXYPHENYL)TETRAHYDROFURAN; 2 [4 [2 (4 CHLOROPHENYLTHIO)ETHOXY] 5 (3 HYDROXY 3 METHYLUREIDOMETHYL) 3 METHOXYPHENYL] 5 (3,4,5 TRIMETHOXYPHENYL)TETRAHYDROFURAN; LIPOXYGENASE INHIBITOR; THROMBOCYTE ACTIVATING FACTOR RECEPTOR AFFECTING AGENT; UNCLASSIFIED DRUG; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; CELL SURFACE RECEPTOR; DRUG DERIVATIVE; ENZYME INHIBITOR; FIBRINOGEN RECEPTOR; FURAN DERIVATIVE; G PROTEIN COUPLED RECEPTOR; LEUKOTRIENE B4; PHORBOL 13 ACETATE 12 MYRISTATE; THROMBOCYTE ACTIVATING FACTOR RECEPTOR; UREA;

ANIMAL MODEL; ARTICLE; BINDING AFFINITY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; ANIMAL; BIOSYNTHESIS; BLOOD; CELL CULTURE; CELL MEMBRANE; CHEMICALLY INDUCED DISORDER; CHEMISTRY; CHO CELL; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; EDEMA; HAMSTER; HEMATOCRIT; METABOLISM; RAT; SYNTHESIS; THROMBOCYTE; ULTRASTRUCTURE;

ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; ARACHIDONIC ACID; BLOOD PLATELETS; CELL MEMBRANE; CHO CELLS; CRICETINAE; DRUG EVALUATION, PRECLINICAL; EDEMA; ENZYME INHIBITORS; FURANS; HEMATOCRIT; HUMANS; LEUKOTRIENE B4; MICE; PLATELET MEMBRANE GLYCOPROTEINS; RATS; RECEPTORS, CELL SURFACE; RECEPTORS, G-PROTEIN-COUPLED; STRUCTURE-ACTIVITY RELATIONSHIP; TETRADECANOYLPHORBOL ACETATE; TUMOR CELLS, CULTURED; UREA;

EID: 15444347390     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980046r     Document Type: Article

References (25)

1. Musser, J. H.; Kreft, A. F. 5-Lipoxygenase: Properties, Pharmacology and the Quinolinyl(bridged)aryl Class of Inhibitors. J. Med. Chem. 1992, 35, 2501-2524.
2. Lewis, R. A.; Austen, K. F.; Soberman, R. J. Leukotrienes and Other Products of the 5-Lipoxygenase pathway. N. Engl. J. Med. 1990, 323, 645-655.
3. Henderson, W. R. The Role of Leukotrienes in inflammation. Ann. Intern. Med. 1994, 121, 684-697.
4. 4, a Potent Chemokinetic and Aggregating Substance Released from Polymorphonuclear Leukocytes. Nature 1980, 286, 264-265.
5. Orange, R. P.; Austen, K. F. Slow Reacting Substance of Anaphylaxis. Adv. Immunol. 1969, 10, 105-144.
6. Snyder, F. Chemical and Biological Aspects of Platelet Activating Factor: A Novel Class of Acetylated Ether-Linked Chloline-Phospholipids. Med. Res. Rev. 1985, 5, 107-140.
7. Shen, T. Y.; Hwang S.-B.; Doebber, T. W.; Robbins, J. C. The Chemical and Biological Properties of PAF Agonists, Antagonists and Biosynthetic Inhibitors. In Platelet-Activating Factor and Related Lipid Mediator, Snyder, F., Ed.; Plenum Press: New York, 1987; pp 152-190.
8. Hwang, S.-B. Specific Receptors of Platelet-Activating Factor, Receptor Heterogeneity, and Signal Transduction Mechanisms. J. Lipid Mediators 1990, 2, 123-158.
9. Hosford, D.; Braquet, P. Antagonists of Platelet-Activating Factor: Chemistry, Pharmacology and Clinical Applications. In Progress in Medicinal Chemistry; Ellis, G. P., West, G. B., Eds.; Elsevier Science Publisher: Amsterdam, 1990; Vol. 27, pp 325-380.
10. Hussoin, M. S.; Yeh, C. G. The Design of Dual-Acting Compounds with PAF Receptor Antagonistic and 5-Lipoxygenase Inhibitory Activities. Drug Future 1996, 21, 933-944.
11. Summers, J. B.; Davidsen, S. K.; Sheppard, G. S. Platelet Activating Factor Antagonists. Curr. Pharm. Des. 1995, 1, 161-190.
12. Batt, D. G. 5-Lipoxygenase Inhibitors and Their Anti-inflammatory Activities. Prog. Med. Chem. 1992, 29, 1-63.
13. Goldstein, D. M.; Shen, T. Y. Dual Inhibitors of Platelet-Activating Factor and 5-Lipoxygenase, 2,4-Diaryl-1,3-Dithiolanes. Med. Chem. Res. 1992, 2, 443.
14. Cai, X.; Hussoin, M. S.; Killian, D. B.; Scannell, R.; Yaeger, D.; Eckman, J.; Hwang, S.-B.; Garahan, L.-L.; Qian, C.; Yeh, G.; Ip, S. Synthesis of Substituted-Hydroxyureidyl diaryltetrahydrofurans, a Potent Class of Dual Inhibitors of 5-Lipoxygenase (5-LO) and Platelet-Activating Factor (PAF), 207th ACS Meeting (March 13-17, San Diego), 1994, MEDI 123.
15. Hussoin, M. S.; Cai, X.; Scannell, R.; Yaeger, D.; Eckman, J.; Hwang, S.-B.; Garahan L.-L.; Qian, C.; Yeh, G.; Ip, S. Platelet Activating Factor and 5- Lipoxygenase Inhibitory Activity of (CMI-206) Hydroxyureidyl Tetrahydrofuran/Tetrahydrothiophene, 208th ACS Meeting (Aug. 21-25, Washington, DC), 1994, MEDI 126.
16. Hussion, M. S.; Cai, X.; Scannell, R.; Yaeger, D.; Killian, D. B.; Eckman, J.; Hwang, S.; Garahan, L.-L.; Qian, C.; Yeh, G.; Ip, S. CMI-206: A potent Dual Platelet Activating Factor antagonist and 5-Lipoxygenase Inhibitor. Bioorg. Med. Chem. Lett. 1995, 5, 643-8.
17. Hussoin, M. S.; Biftu, T.; Cai, X.; Scannell, R.; Grewal G.; Young M.; Yaeger, D.; Killian, D. B.; Wypij D.; Lobell R.; Eckman, J.; Garahan, L.-L.; Qian, C.; Yeh, G. Synthesis and Biological Activity of a Potent Dual-Acting Platelet Activating Factor and 5-Lipoxygenase Inhibitor. 211th ACS Meeting (March 24-28, New Orleans), 1996, MEDI 205.
18. Girotra, N.N.; Biftu, T.; Ponpipom, M. M.; Acton, J. J.; Alberts, A. W.; Bach, T. N.; Ball, R.G.; Bugianeasi, R. L.; Parson, W. H.; Chabala, J.C.; Davies, P.; Doebber, T.W.; Doherty, J.; Graham, D.W.; Hwang, S. B.; Kuo, C. H.; Lam, M.-H.; Luell, S.; MacIntyre, D.E.; Meurer, R.; Roberts, C.D.; Sahoo, S. P.; Wu, M. S. Development, Synthesis, and Biological Evaluation of (-)-trans-(2S, 5S)-2-[3-[(2-Oxopropyl)sulfonyl]-4-n-propoxy-5-(3-hydroxypropoxy)-phenyl]-5-(3, 4,5-trimethoxyphenyl) tetrahydrofuran, a Potent Orally Active Platelet-Activating Factor (PAF) Antagonist and Its Water-Soluble Prodrug Phosphate Ester. J. Med. Chem. 1992, 35, 3474-3482.
19. Sirois, P.; Borgeat, P.; Lauziere, M.; Dube, L.; Rubin, P.; Kesterson, J. Effect of Zileuton (A-64077) on the 5-Lipoxygenase Activity of Human Whole Blood ex Vivo. Agents Action 1991, 34, 117-120.
20. Carter, G. W.; Young, P. R.; Albert, D. H.; Bouska, J.; Dyer, R.; Bell, R. L.; Summers, J. B.; Brooks, D. W. 5-Lipoxygenase Inhibitory Action of Zileuton. J. Pharmacol. Exp. Ther. 1991 256, 929-937.
21. Inarrea, P.; Alonso, F.; Sanchez-Crespo, M. Platelet-Activating Factor: an Effector Substance of the Vasopermeability Changes Induced by the Infusion of Immune Aggregates in the Mouse. Immunopharmacology 1983, 6, 7-14.
22. Carlson, R. P.; O'Neill-Davis, L.; Chang, J.; Lewis, A. J. Modulation of Mouse Ear Edema by Cyclooxygenase and Lipoxygenase Inhibitors and other Pharmacologic Agents. Agents Action 1985, 17, 197-204.
23. Opas, E. E.; Bonney, R. J.; Humes, J. L. Prostaglandin and Leukotriene Synthesis in Mouse Ears Inflamed by Arachidonic Acid. J. Invest. Dermatol. 1985, 84, 253-256.
24. Bradley, P. P.; Priebat, D. A.; Christensen, R. D.; Rothetein, G. Measurement of Cutaneous Inflammation: Estimation of Neutrophil Content with an Enzyme Marker. J. Invest Dermatol. 1982, 78, 206-209.
25. Obtained from Societe de Conseils de Recherches et d'Applications Scientifiques.